股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 奧星生命科技有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 奧星生命科技有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | 本月底法 ...

Core Viewpoint - Aoxing Life Science Technology (06118) has seen a significant stock price increase, with a rise of over 54% at the close, currently trading at 1.51 HKD, with a transaction volume of 8.4778 million HKD [1] Company Overview - Aoxing Group is a technology-based pharmaceutical engineering solution provider [1] - The business of Aoxing Life Science includes nine segments: sterile drug production contamination control consumables, equipment and services, environmental monitoring and testing systems, validation and single equipment, biological upstream process systems, disposable process systems, laboratory information technology, and life science consulting [1] Financial Performance - Aoxing Life Science reported a net profit attributable to shareholders of 24.999 million HKD, representing a year-on-year increase of 325.37% [1]

Core Viewpoint - Aoxing Life Science Technology (06118) has seen a significant stock price increase, with a rise of over 54% towards the end of trading, currently up 48.04% at HKD 1.51, with a trading volume of HKD 8.4778 million [1] Company Overview - Aoxing Group is a technology-based pharmaceutical engineering solution provider based in Hong Kong [1] - The business of Aoxing Life Science includes nine segments: sterile drug production contamination control consumables, equipment and services, environmental monitoring and testing systems, validation and single equipment, biological upstream process systems, disposable process systems, laboratory information technology, and life science consulting [1] Financial Performance - Aoxing Life Science reported a mid-term profit attributable to shareholders of HKD 24.999 million, representing a year-on-year increase of 325.37% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 奧星生命科技有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定 ...

奧星生命科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Current Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications (Note 2) in printed form, please complete, sign the enclosed Request Form and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limi ...

Austar Lifesciences Limited 奧星生命科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：6118） NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 25 September 2025 Austar Lifesciences Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.austar.com.hk and the website of Th ...

Financial Performance - For the six months ended June 30, 2025, the company's revenue was RMB 661,905,000, a decrease of 5.5% compared to RMB 700,919,000 in the same period of 2024[10]. - Gross profit for the same period was RMB 139,143,000, down from RMB 145,417,000, resulting in a gross margin of 21.0%, slightly up from 20.7% in 2024[10]. - Profit before tax increased significantly to RMB 30,303,000, compared to RMB 9,186,000 in the previous year, indicating a growth of 229.5%[10]. - Net profit attributable to shareholders was RMB 24,999,000, a substantial increase from RMB 5,877,000 in 2024, reflecting a growth of 325.5%[10]. - Total revenue for the group was approximately RMB 661.9 million, a decrease of about 5.6% compared to the previous six months ending June 30, 2024[52]. - Operating profit increased significantly to RMB 34,753 thousand, compared to RMB 17,254 thousand in the previous year, marking a growth of 101.5%[118]. - Net profit for the period was RMB 23,614 thousand, a substantial increase from RMB 4,189 thousand in 2024, representing a growth of 463%[119]. - Basic and diluted earnings per share rose to RMB 0.05, compared to RMB 0.01 in the prior year[119]. Assets and Liabilities - Total assets as of June 30, 2025, were RMB 2,028,382,000, a slight decrease from RMB 2,083,635,000 at the end of 2024[10]. - The company's equity attributable to owners was RMB 809,352 thousand, an increase from RMB 791,409 thousand[122]. - As of June 30, 2025, total liabilities amounted to RMB 1,218,015 thousand, a decrease from RMB 1,290,167 thousand as of December 31, 2024, representing a reduction of approximately 5.6%[124]. - The company's debt-to-equity ratio improved from approximately 33.9% as of December 31, 2024, to about 30.9% as of June 30, 2025[82]. - The total value of uncompleted contracts was approximately RMB 1,327.6 million, with the integrated process and packaging equipment system accounting for 53.4% of this value[28]. Revenue Segmentation - Revenue from the Integrated Process and Packaging Equipment Systems segment increased by approximately RMB 8.8 million or 2.9% to about RMB 318.1 million[54]. - Revenue from the Consulting, Digitalization, and Construction segment decreased by approximately RMB 26.5 million or 12.2% to about RMB 190.1 million[55]. - Revenue from the Life Science Equipment and Consumables segment decreased by approximately RMB 21.4 million or 12.2% to about RMB 153.7 million[56]. - Revenue from mainland China accounted for approximately 90.2% of total revenue, down from 93.0% in the previous period[58]. Strategic Focus and Investments - The company is focusing on strategic investments in advanced therapeutic digital infrastructure, particularly in cell and gene therapy and mRNA vaccine technologies[13]. - The market for GLP-1 peptide drugs is experiencing significant growth, driven by increasing demand for obesity treatments, with multiple projects underway[14]. - The company is exploring opportunities in the nuclear medicine sector, with a focus on diagnostic and therapeutic applications, particularly in prostate cancer and neuroendocrine tumors[15]. - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" is expected to create new project opportunities in the pharmaceutical sector[14]. Operational Efficiency - The group is focusing on global expansion, particularly in key regions such as the Middle East, North Africa, Southeast Asia, Europe, South America, and North America[51]. - The integrated process and packaging equipment system business group saw a substantial growth of 32.3%, with order amount approximately RMB 569.6 million compared to RMB 430.7 million in 2024[21]. - The consulting, digitalization, and construction business group recorded an order amount of approximately RMB 302.7 million, an increase of about RMB 12.2 million or 4.2%[22]. - The life science equipment and consumables business group experienced a decrease in order amount by approximately RMB 15.4 million or 8.4%, totaling around RMB 169.5 million[24]. Research and Development - The company has launched the ContiPI continuous wet granulation and drying system, enhancing its service platform for innovative drug development[39]. - The company continues to deepen its expertise in complex production processes for APIs, particularly in the fields of peptides and small nucleic acids[19]. - The company has invested in a series of sterile transfer and containment products, which have successfully entered commercial production and been supplied to leading biotech firms[34]. - Research and development expenses decreased by approximately RMB 7.0 million or 29.8% to about RMB 16.5 million, attributed to lower employee costs and material expenses[68]. Corporate Governance and Compliance - The company has adopted and is committed to implementing the corporate governance code, ensuring compliance with the relevant provisions[104]. - The audit committee reviewed the group's unaudited condensed interim financial information for the review period[108]. - The group did not declare any interim dividend for the six months ending June 30, 2025, consistent with the previous year[84]. Employee and Management Changes - The total employee cost for the review period was approximately RMB 178.0 million, representing an increase of about 2.9% from RMB 172.9 million for the six months ending June 30, 2024[87]. - The group employed 1,446 full-time employees as of June 30, 2025, a slight increase from 1,445 employees as of December 31, 2024[87]. - Mr. He Guoqiang's annual salary has been adjusted from HKD 1,024,500 to HKD 819,600, effective from February 26, 2025[99]. - Ms. Zhao Kaishan resigned as an independent non-executive director of Hengfu Holdings Limited, effective from June 16, 2025[99].

公司名稱: 奧星生命科技有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Core Viewpoint - Aoxing Life Science Technology (06118.HK) reported a decrease in revenue for the first half of 2025, but significant growth in net profit and order intake, indicating resilience in key projects and operational efficiency [1] Financial Performance - Revenue for the first half of 2025 was RMB 662 million, a decrease of 5.57% year-on-year [1] - Profit attributable to owners increased to RMB 24.999 million, a year-on-year growth of 325.37% [1] - Basic earnings per share were RMB 0.05 [1] Order and Project Performance - Total order amount for the first half of 2025 was approximately RMB 1.0418 billion, an increase of about RMB 135.7 million or 15.0% year-on-year [1] - The integrated process and packaging equipment systems business saw a significant growth of 32.3% [1] - Consulting, digitalization, and construction business segments also experienced a growth of 4.2% [1] Cash Flow and Profitability - Net profit after tax showed a significant increase compared to the same period in 2024 [1] - Operating cash flow increased by over 99% compared to 2024 [1]